1. Market Research
  2. > Biotechnology Market Trends
  3. > Global Antibody Partnering 2010-2015: Deal trends, players and financials

The Global Antibody Partnering 2010-2015: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

Antibodies
Antibody-drug conjugates
Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human mAb
Polyclonal Antibodies

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains a comprehensive listing of all antibody partnering deals announced since January 2010, including financial terms where available, including over 900 links to online deal records of actual antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report takes readers through the antibody deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering antibody partnering deals.

The report presents average financial deal terms values for antibody deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the antibody partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 900 online deals records of actual antibody deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?


Finally the report concludes by looking into the future of antibody partnering. With so many innovators looking for the next big thing in the field, the report selects companies to watch who are predicted to become big in the field based on their current dealmaking and financial trends.

Throughout the report various tables, figures and graphs are embedded in order to illustrate the trends and partnering activities of the antibody field.

By the end of the report prospective dealmakers will have gained a thorough understanding of the partnering landscape of the antibody market and will be familiar with the values and structures of the deals being signed within it.

Report scope

Global Antibody Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to antibody trends and structure of deals entered into by leading companies worldwide.

Global Antibody Partnering 2010-2015 includes:

Trends in antibody dealmaking in the biopharma industry since 2009
Analysis of antibody deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life antibody deals
Access to over 900 antibody deal records and contract documents where available
The leading antibody deals by value since 2009
Most active antibody dealmakers since 2009
The leading antibody partnering resources

In Global Antibody Partnering 2010-2015, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Antibody Partnering 2010-2015 report provides comprehensive access to available deals and contract documents for over 900 antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise antibody rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law'Global Antibody Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of antibody deal trends since 2010
Access to headline, upfront, milestone and royalty data
Analysis of the structure of antibody agreements with numerous real life case studies
Comprehensive access to over 900 actual antibody deals entered into by the world’s biopharma companies, together with contract documents if available
Detailed access to actual antibody contracts enter into by the leading companies
Identify leading antibody deals by value since 2010
Identify the most active antibody dealmakers since 2010
Insight into the terms included in a antibody agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Antibody Partnering 2010-2015: Deal trends, players and financials
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

2.1. Introduction
2.2. Antibody partnering over the years
2.3. Big pharma antibody dealmaking activity
2.4 Big Biotech antibody dealmaking activity
2.5. Top 10 active antibody dealmakers
2.6. Antibody partnering by deal type
2.7. Antibody partnering by disease type
2.8. Antibody partnering by stage of development
2.9. Partnering by antibody type
2.10. Average deal terms for antibody partnering
2.10.1 Antibody partnering by headline values
2.10.2 Antibody partnering by upfront payments
2.10.3 Antibody partnering by milestone payments
2.10.4 Antibody partnering by royalty rates
2.11. The anatomy of antibody partnering
2.11. The anatomy of an antibody deal
2.11.a. Case study 1: ADMA Biologics- Biotest: December 31 2012
2.11.b. Case study 2: Amgen- AstraZeneca: April 2, 2012

Chapter 3 - Leading antibody deals

3.1. Introduction
3.2. Top antibody deals by value

Chapter 4 - Big pharma antibody deals

4.1. Introduction
4.2. How to use big pharma antibody partnering deals
4.3. Big pharma antibody partnering company profiles

Chapter 5 - Big Biotech antibody deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech antibody partnering company profiles

Chapter 6 - Antibody dealmaking directory with contract documents

6.1. Introduction
6.2. Antibody dealmaking with contract documents by company A-Z
6.3. Antibody dealmaking with contract documents by stage of development
6.4. Antibody dealmaking with contract documents by deal type
6.5. Antibody dealmaking with contract documents by therapy area

Chapter 7- Antibody dealmaking by antibody technology type

7.1. Introduction
7.2. Deals by antibody type


Chapter 8 - Antibody partnering resource center

8.1. Online antibody partnering
8.2. Antibody partnering events
8.3. Further reading on antibody dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Upgrades to subscription access products
Order Form - Reports

Appendices

Appendix 1- Antibody deals by company A-Z
Appendix 2- Antibody deals by stage of development
Appendix 3- Antibody deals by deal type
Appendix 4- Antibody deals by therapy area


Table of figures

Figure 1: Therapeutic antibody definitions
Figure 2: Antibody partnering since 2009
Figure 3: Big pharma - top 50 - antibody deals 2009 to 2014
Figure 4: Big pharma antibody deal frequency - 2009 to 2014
Figure 5: Big biotech - top 50 - antibody deals 2009 to 2014
Figure 6: Big biotech antibody deal frequency - 2009 to 2014
Figure 7: Top 10 antibody dealmakers - 2009 to 2014
Figure 8: Antibody partnering by deal type since 2009
Figure 9: Antibody partnering by disease type since 2009
Figure 10: Antibody partnering by oncology target since 2009
Figure 11: Antibody partnering by stage of development since 2009
Figure 12: Antibody partnering by therapeutic antibody type since 2009
Figure 13: Antibody deals with a headline value by year- 2014
Figure 14: Antibody deals with a headline value by year- 2013
Figure 15: Antibody deals with a headline value by year- 2012
Figure 16: Antibody deals with a headline value by year- 2011
Figure 17: Antibody deals with a headline value by year- 2010
Figure 18: Antibody deals with a headline value by year- 2009
Figure 19: Antibody deal by headline value distribution, US$million - 2014
Figure 20: Antibody deal by headline value distribution, US$million - 2013
Figure 21: Antibody deal by headline value distribution, US$million - 2012
Figure 22: Antibody deal by headline value distribution, US$million - 2011
Figure 23: Antibody deal by headline value distribution, US$million - 2010
Figure 24: Antibody deal by headline value distribution, US$million - 2009
Figure 25: Summary median headline value by year, 2009-2014
Figure 26: Antibody deals with an upfront value by year- 2014
Figure 27: Antibody deals with an upfront value by year- 2013
Figure 28: Antibody deals with an upfront value by year- 2012
Figure 29: Antibody deals with an upfront value by year- 2011
Figure 30: Antibody deals with an upfront value by year- 2010
Figure 31: Antibody deals with an upfront value by year- 2009
Figure 32: Antibody deal by upfront value distribution, US$million - 2014
Figure 33: Antibody deal by upfront value distribution, US$million - 2013
Figure 34: Antibody deal by upfront value distribution, US$million - 2012
Figure 35: Antibody deal by upfront value distribution, US$million - 2011
Figure 36: Antibody deal by upfront value distribution, US$million - 2010
Figure 37: Antibody deal by upfront value distribution, US$million - 2009
Figure 38: Summary median upfront value by year, 2009-2014
Figure 39: Antibody deals with a milestone value by year- 2014
Figure 40: Antibody deals with a milestone value by year- 2013
Figure 41: Antibody deals with a milestone value by year- 2012
Figure 42: Antibody deals with a milestone value by year- 2011
Figure 43: Antibody deals with a milestone value by year- 2010
Figure 44: Antibody deals with a milestone value by year- 2009
Figure 45: Antibody deal by milestone value distribution, US$million - 2014
Figure 46: Antibody deal by milestone value distribution, US$million - 2013
Figure 47: Antibody deal by milestone value distribution, US$million - 2012
Figure 48: Antibody deal by milestone value distribution, US$million - 2011
Figure 49: Antibody deal by milestone value distribution, US$million - 2010
Figure 50: Antibody deal by milestone value distribution, US$million - 2009
Figure 51: Antibody deals with a royalty rate by year- 2014
Figure 52: Antibody deals with a royalty rate value by year- 2013
Figure 53: Antibody deals with a royalty rate value by year- 2012
Figure 54: Antibody deals with a royalty rate value by year- 2011
Figure 55: Antibody deals with a royalty rate value by year- 2010
Figure 56: Antibody deals with a royalty rate value by year- 2009
Figure 57: Antibody deal by royalty rate value distribution, US$million - 2014
Figure 58: Antibody deal by royalty rate value distribution, US$million - 2013
Figure 59: Antibody deal by royalty rate value distribution, US$million - 2012
Figure 60: Antibody deal by royalty rate value distribution, US$million - 2011
Figure 61: Antibody deal by royalty rate value distribution, US$million - 2010
Figure 62: Antibody deal by royalty rate value distribution, US$million - 2009
Figure 63: Summary median royalty rate by year, 2009-2014
Figure 64: Components of the typical antibody deal structure
Figure 65: Top antibody deals by value since 2009
Figure 66: Online partnering resources
Figure 67: Forthcoming partnering events

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

  • $ 18000
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global bioreactors market is expected to reach to USD 1,417 million by 2021 from USD 955 million in 2015, at a CAGR of 6.8% between 2015 and 2021.The increase in adoption of single-use technologies, ...

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.